Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CADL Candel Therapeutics, Inc.

Pre-Mkt 07-06 04:29:33 EDT

9.83

-0.05

-0.51%

盘前9.66

-0.17-1.73%

04:14 EDT

High10.17	Low9.57	Vol1.55M
Open9.97	D1 Closing9.88	Amplitude6.07%
Mkt Cap719.99M	Tradable Cap558.43M	Total Shares73.24M
T/O15.23M	T/O Rate2.73%	Tradable Shares56.81M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CADL","market":"US","secType":"STK","nameCN":"Candel Therapeutics, Inc.","latestPrice":9.83,"timestamp":1783022400000,"preClose":9.88,"halted":0,"volume":1550102,"hourTrading":{"tag":"盘前","latestPrice":9.66,"preClose":9.83,"latestTime":"04:14 EDT","volume":45,"amount":439.89003,"timestamp":1783325689526,"change":-0.17,"changeRate":-0.017294,"amplitude":0.045778},"delay":0,"changeRate":-0.005060728744939342,"floatShares":56808500,"shares":73244500,"eps":-0.973062,"marketStatus":"Pre-Mkt","change":-0.05,"latestTime":"07-06 04:29:33 EDT","open":9.97,"high":10.17,"low":9.57,"amount":15229928.861628,"amplitude":0.060729,"askPrice":10.75,"askSize":100,"bidPrice":8.69,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.973062,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1783344600000},"marketStatusCode":1,"adr":0,"listingDate":1627358400000,"exchange":"NASDAQ","adjPreClose":9.83,"preHourTrading":{"tag":"盘前","latestPrice":9.66,"preClose":9.83,"latestTime":"04:14 EDT","volume":45,"amount":439.89003,"timestamp":1783325689526,"change":-0.17,"changeRate":-0.017294,"amplitude":0.045778},"postHourTrading":{"tag":"盘后","latestPrice":9.8,"preClose":9.83,"latestTime":"18:50 EDT","volume":31071,"amount":305416.6854,"timestamp":1783032657490,"change":-0.03,"changeRate":-0.003052,"amplitude":0.003052},"volumeRatio":0.6200165945199092,"impliedVol":0.9622,"impliedVolPercentile":0.432},"requestUrl":"/m/hq/s/CADL/wiki","defaultTab":"wiki","newsList":[{"id":"2648269285","title":"Candel Therapeutics CTO Seshu Tyagarajan Sells 7,000 Common Shares for $70,151.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2648269285","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648269285?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:22","pubTimestamp":1782937376,"startTime":"0","endTime":"0","summary":"Candel Therapeutics CTO Seshu Tyagarajan sells 7,000 common shares for $70,151.20Candel Therapeutics Chief Technology Officer Seshu Tyagarajan sold 7,000 common shares on June 29, 2026.Sale priced at ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL2wXt9Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Candel Therapeutics CTO Seshu Tyagarajan Sells 7,000 Common Shares for $70,151.20","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648525266","title":"Candel Therapeutics Grants New Hire Options for 25,000 Shares at $10.3 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2648525266","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648525266?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:05","pubTimestamp":1782936335,"startTime":"0","endTime":"0","summary":"Candel Therapeutics grants new hire options for 25,000 shares at $10.3 eachCandel Therapeutics granted one new employee stock options to buy 25,000 common shares, priced at USD 10.3 per share.Award is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL14vjDy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","SG9999014039.USD","BK4112","LU0314104364.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","SG9999014021.USD","CADL","LU2210149790.SGD","LU2210150020.SGD","LU2095319765.USD","BK4585","BK4588","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4539","BK4139","NDAQ","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648526897","title":"Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2648526897","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648526897?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:05","pubTimestamp":1782936300,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., July  01, 2026  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immuno","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/01/3320980/0/en/Candel-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CADL","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647568931","title":"Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2647568931","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647568931?lang=en_us&edition=fundamental","pubTime":"2026-06-30 23:56","pubTimestamp":1782834960,"startTime":"0","endTime":"0","summary":"Shares of Candel Therapeutics rose after the company said it was initiating a pivotal Phase 3 trial to evaluate a lung-cancer treatment.Shares were up 8.4% to $11.23 in trading midday Tuesday. The stock has nearly doubled in value this year.The company said Tuesday that it had engaged the clinical-research organization Parexel International to help execute the trial, which will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab for patients with metastatic, non-squamous non-small cell lung cancer whose disease has progressed despite treatment with pembrolizumab and platinum-based chemotherapy.The trial is expected to enroll patients across 150 sites, with a primary endpoint of overall survival and secondary endpoints including safety and quality-of-life assessments, said Candel.The drug has been granted fast-track designation by the Food and Drug Administration, the biopharmaceutical company said.\"Building on our completed Phase 2 clinical t","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-cancer Drug","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CADL","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647553011","title":"Candel Therapeutics Launches Phase 3 Aurora Trial of Can-2409 Combo in Advanced NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2647553011","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647553011?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:06","pubTimestamp":1782821166,"startTime":"0","endTime":"0","summary":"Candel Therapeutics launches Phase 3 AURORA trial of CAN-2409 combo in advanced NSCLCCandel Therapeutics launched the global pivotal Phase 3 AURORA trial of CAN-2409 with valacyclovir alongside contin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL6c4r0F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4112","SG9999014013.SGD","LU2210149790.SGD","BK4539","NDAQ","BK4139","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BN0W2W23.USD","SG9999014021.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","LU0314104364.USD","IE00B64PRP62.GBP","CADL","BK4588","IE00BGHQF748.EUR","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647553449","title":"Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 Aurora Trial Evaluating Aglatimagene Besadenovec (can-2409) in Advanced Non-small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2647553449","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647553449?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:05","pubTimestamp":1782821100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA7BYCKD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646870624","title":"Candel Therapeutics Names Mark Sims Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2646870624","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646870624?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:05","pubTimestamp":1782389116,"startTime":"0","endTime":"0","summary":"Candel Therapeutics names Mark Sims chief commercial officerCandel named Mark Sims chief commercial officer, effective July 6, 2026, to lead launch readiness for aglatimagene besadenovec in localized ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL1dydSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646870616","title":"Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2646870616","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646870616?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:05","pubTimestamp":1782389100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUABQTFW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646891849","title":"Candel Therapeutics Stockholders Approve Directors and Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2646891849","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646891849?lang=en_us&edition=fundamental","pubTime":"2026-06-25 04:48","pubTimestamp":1782334092,"startTime":"0","endTime":"0","summary":"The latest update is out from Candel Therapeutics ( ($CADL) ). Candel Therapeutics, Inc. held its Annual Meeting of Stockholders on June 23, 2026, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/candel-therapeutics-stockholders-approve-directors-and-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/candel-therapeutics-stockholders-approve-directors-and-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646845765","title":"Candel Therapeutics Shareholders Elected Four Class II Directors at Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2646845765","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646845765?lang=en_us&edition=fundamental","pubTime":"2026-06-25 04:27","pubTimestamp":1782332869,"startTime":"0","endTime":"0","summary":"Candel Therapeutics shareholders elected four Class II directors at annual meetingCandel Therapeutics held its annual shareholder meeting on June 23, 2026.Shareholders backed the selection of four dir","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL7jccTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644798004","title":"Candel Therapeutics Updates Employment Agreement with Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2644798004","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644798004?lang=en_us&edition=fundamental","pubTime":"2026-06-17 05:13","pubTimestamp":1781644399,"startTime":"0","endTime":"0","summary":"An announcement from Candel Therapeutics ( ($CADL) ) is now available. On June 12, 2026, Candel Therapeutics entered into a new employment agreemen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/candel-therapeutics-updates-employment-agreement-with-chief-financial-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/candel-therapeutics-updates-employment-agreement-with-chief-financial-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644760529","title":"Candel Therapeutics CFO Schoch employment agreement keeps base salary at $468,600, bonus target 40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644760529","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644760529?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:24","pubTimestamp":1781641473,"startTime":"0","endTime":"0","summary":"Candel Therapeutics entered an employment agreement on June 12, 2026 with CFO Charles Schoch, keeping his role on an at-will basis.Annual base salary stays at $468,600; annual bonus target remains 40% of base salary.Termination without cause or for good reason triggers 9 months of base salary plus target bonus, paid over 9 months.Company-paid health premium support continues for up to 9 months under COBRA, subject to eligibility limits.Time-based equity awards fully accelerate if termination occurs within 1 month before or 12 months after a change in control.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL3261sY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640942768","title":"Analyst Reiterates Buy Rating on Strengthened Phase 3 Data for Aglatimagene Besadenovec, Maintains $23 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2640942768","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640942768?lang=en_us&edition=fundamental","pubTime":"2026-06-03 00:45","pubTimestamp":1780418739,"startTime":"0","endTime":"0","summary":"In a report released today, Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on Candel Therapeutics, with a price target of $23.00....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-rating-on-strengthened-phase-3-data-for-aglatimagene-besadenovec-maintains-23-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-rating-on-strengthened-phase-3-data-for-aglatimagene-besadenovec-maintains-23-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640054949","title":"Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene","url":"https://stock-news.laohu8.com/highlight/detail?id=2640054949","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640054949?lang=en_us&edition=fundamental","pubTime":"2026-06-02 22:27","pubTimestamp":1780410443,"startTime":"0","endTime":"0","summary":"Candel Therapeutics (CADL) announced the publication of results from its pivotal Phase 3 trial of Aglatimagene in The Lancet Oncology. The trial, w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-publishes-pivotal-phase-3-data-for-aglatimagene-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-publishes-pivotal-phase-3-data-for-aglatimagene-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640948305","title":"Candel Therapeutics says Phase 3 trial shows 30% disease-free survival gain for CAN-2409 in localized prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2640948305","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640948305?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:09","pubTimestamp":1780402174,"startTime":"0","endTime":"0","summary":"Candel Therapeutics flagged a peer-reviewed Lancet Oncology publication of pivotal Phase 3 results for CAN-2409 in localized prostate cancer.Results were previously disclosed in December 2024, with extended follow-up presented at the American Urological Association 2026 meeting.Trial outcome showed fewer disease recurrences when CAN-2409 was added to curative-intent radiotherapy versus radiotherapy alone.Safety profile remained broadly consistent with standard treatment, with no meaningful increase in clinically significant toxicity.Data are expected to underpin a planned biologics license application submission in Q4 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL3YTZRY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4588","BK4112","SG9999014021.USD","BK4585","LU2210150020.SGD","LU2095319765.USD","IE00BN0W2V16.EUR","BK4139","SG9999014039.USD","SG9999014005.SGD","LU0314104364.USD","IE00BN0W2W23.USD","CADL","SG9999014013.SGD","NDAQ","LU2210149790.SGD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","BK4539","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640943331","title":"Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2640943331","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640943331?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:05","pubTimestamp":1780401900,"startTime":"0","endTime":"0","summary":"Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing standard-of-care radiotherapy with cu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305133/0/en/Candel-Therapeutics-Announces-Publication-in-The-Lancet-Oncology-of-Pivotal-Phase-3-Data-Demonstrating-Significant-Improvement-in-Disease-Free-Survival-with-Aglatimagene-Besadenove.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640964540","title":"Candel Therapeutics grants inducement stock options for 63,000 shares at $8.3 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2640964540","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640964540?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:08","pubTimestamp":1780344519,"startTime":"0","endTime":"0","summary":"Candel Therapeutics granted inducement stock options covering 63,000 shares to three new employees on May 31, 2026.Vesting schedule: 25% after one year from start date; remaining 75% vests monthly over the next 36 months.Awards were issued under the company’s 2025 Inducement Plan, adopted Dec. 24, 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL4D5JkG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B3QW5Z07.USD","NDAQ","SG9999014013.SGD","SG9999014021.USD","LU2095319765.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4539","LU2210149790.SGD","LU0314104364.USD","CADL","IE00BKPKM429.USD","BK4112","SG9999014005.SGD","BK4588","BK4585","IE00BN0W2V16.EUR","SG9999014039.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640296412","title":"Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640296412","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640296412?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:05","pubTimestamp":1780344300,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., June  01, 2026  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immuno","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304707/0/en/Candel-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CADL","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640136984","title":"Bank of America Securities Remains a Hold on Candel Therapeutics (CADL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640136984","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640136984?lang=en_us&edition=fundamental","pubTime":"2026-06-01 09:19","pubTimestamp":1780276745,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Hold rating on Candel Therapeutics, with a price target...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-remains-a-hold-on-candel-therapeutics-cadl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-remains-a-hold-on-candel-therapeutics-cadl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1506573853.SGD","LU0256863902.USD","BK4504","BAC","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU0314106906.USD","LU0971096721.USD","LU2265009873.SGD","LU0098860793.USD","LU0052756011.USD","BK4539","LU0648001328.SGD","LU1880398554.USD","LU0211331839.USD","BK4581","LU0477156953.USD","LU0683600562.USD","PGF","LU1074936037.SGD","LU0149725797.USD","LU1894683348.USD","LU0130102774.USD","IE0002270589.USD","LU1883839398.USD","IE00BLSP4239.USD","BK4553","LU1496350502.SGD","LU0980610538.SGD","LU1366192091.USD","CADL","LU0320765646.SGD","IE00B1BXHZ80.USD","LU1201861165.SGD","LU1162221912.USD","LU0203345920.USD","BK4582","LU1035773651.USD","LU2129689605.HKD","LU1267930227.SGD","LU0640476718.USD","LU0128525689.USD","LU0106831901.USD","LU1280957306.USD","LU0477156797.USD","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","BK4207","IE00BZ1G4Q59.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636300636","title":"Candel Therapeutics price target raised to $9 from $7 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2636300636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636300636?lang=en_us&edition=fundamental","pubTime":"2026-05-19 03:30","pubTimestamp":1779132609,"startTime":"0","endTime":"0","summary":"BofA analyst Alec Stranahan raised the firm’s price target on Candel Therapeutics (CADL) to $9 from $7 and keeps a Neutral rating on the shares. Ca...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-price-target-raised-to-9-from-7-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-price-target-raised-to-9-from-7-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CADL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.candeltx.com","stockEarnings":[{"period":"1week","weight":0.038},{"period":"1month","weight":0.1675},{"period":"3month","weight":0.966},{"period":"6month","weight":0.807},{"period":"1year","weight":0.9699},{"period":"ytd","weight":0.7398}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.056687},{"month":2,"riseRate":0.4,"avgChangeRate":0.052018},{"month":3,"riseRate":0.2,"avgChangeRate":-0.120448},{"month":4,"riseRate":0.4,"avgChangeRate":0.650234},{"month":5,"riseRate":1,"avgChangeRate":0.18781},{"month":6,"riseRate":0.2,"avgChangeRate":-0.088023},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000306},{"month":8,"riseRate":0.8,"avgChangeRate":0.068985},{"month":9,"riseRate":0.4,"avgChangeRate":-0.01705},{"month":10,"riseRate":0.4,"avgChangeRate":-0.110246},{"month":11,"riseRate":0,"avgChangeRate":-0.079739},{"month":12,"riseRate":0.8,"avgChangeRate":0.288433}],"exchange":"NASDAQ","name":"Candel Therapeutics, Inc.","nameEN":"Candel Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.1","shortVersion":"4.45.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Candel Therapeutics, Inc.(CADL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Candel Therapeutics, Inc.,CADL,Candel Therapeutics, Inc.股票,Candel Therapeutics, Inc.股票老虎,Candel Therapeutics, Inc.股票老虎国际,Candel Therapeutics, Inc.行情,Candel Therapeutics, Inc.股票行情,Candel Therapeutics, Inc.股价,Candel Therapeutics, Inc.股市,Candel Therapeutics, Inc.股票价格,Candel Therapeutics, Inc.股票交易,Candel Therapeutics, Inc.股票购买,Candel Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Candel Therapeutics, Inc.(CADL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}